ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Financial Statements and Exhibits

49

ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

1.1 Sales Agreement, dated August11, 2017, by and between Antares Pharma, Inc. and Cowen and Company, LLC
5.1 Opinion of Morgan, Lewis& Bockius LLP
23.1 Consent of Morgan, Lewis& Bockius LLP (included in Exhibit 5.1)


ANTARES PHARMA, INC. Exhibit
EX-1.1 2 d440694dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version ANTARES PHARMA,…
To view the full exhibit click here

About ANTARES PHARMA, INC. (NASDAQ:ATRS)

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

An ad to help with our costs